Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Frank Karbe Insider Profile
11 Followers
Frank Karbe, Director at Arbutus Biopharma, holds 44.50K shares in Phathom Pharmaceuticals (Ticker: PHAT), holds 526.52K shares in Better Therapeutics, Inc. (Ticker: BTTX), holds 212.30K shares in Myovant Sciences (Ticker: MYOV).
Profitable Transactions
3 out of 5 Profitable Transactions
Average Return
-3.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Frank Karbe holds in companies
Most Profitable Insider Trade
Stock:
Myovant Sciences
(MYOV)
(MYOV)
Rating:Informative Buy
Date:Jun 11, 2019 - Jun 11, 2020
Return:+76.00%
The most profitable trade made by Frank Karbe
Frank Karbe's Trading History
Arbutus Biopharma
Dec 31, 2014
Director
Uninformative Buy
―
$17.20K
Myovant Sciences
Jul 09, 2021
―
Informative Sell
70.30K
$5.73M
Chinook Therapeutics
―
―
―
―
Phathom Pharmaceuticals
May 31, 2024
Director
Uninformative Buy
254.00K
$388.49K
Better Therapeutics, Inc.
Dec 20, 2023
CEO, Director
Uninformative Buy
―
$5.27K
Exelixis
Nov 17, 2011
EVP & CFO
Uninformative Buy
―
$3.67M
List of latest transactions for each holding click on a transaction to see Frank Karbe's performance on stock
You May Also Like
Frank Karbe insider profile FAQ
What is the percentage of profitable transactions made by Frank Karbe?
The percentage of profitable transactions made by Frank Karbe is 60%.
What is the average return per transaction made by Frank Karbe?
The average return per transaction made by Frank Karbe is -3.30%.
What stocks does Frank Karbe hold?
Frank Karbe holds: ABUS, MYOV, KDNY, PHAT, BTTX, EXEL stocks.
What was Frank Karbe’s latest transaction?
Frank Karbe latest transaction was an Uninformative Buy of $254.00K.
What was Frank Karbe's most profitable transaction?
Frank Karbe’s most profitable transaction was an Informative Buy of MYOV stock on June 11, 2019. The return on the trade was 76.00%.
What is Frank Karbe's role in Arbutus Biopharma?
Frank Karbe's role in Arbutus Biopharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.